Literature DB >> 8898414

Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis.

J G Hatlebakk1, A Berstad.   

Abstract

BACKGROUND: Tolerance has been shown to develop in duodenal ulcer patients receiving H2-receptor antagonists, particularly with increased doses. Development of tolerance to ranitidine and its possible consequences for oesophageal acid load in patients with gastro-oesophageal reflux disease has still to be established.
METHODS: Eighteen patients with reflux oesophagitis grade 1 were treated with 300 mg ranitidine twice daily for 3 months and examined with two-channel 23-h pH-metry in the distal oesophagus and gastric body at base line and after 3 days and 3 months. Gastric infection with Helicobacter pylori was assessed with the 14C urea breath test.
RESULTS: Median 23-h gastric pH increased significantly from 1.5 at base line to 3.7 on day 3 and 2.8 after 3 months but decrease significantly from day 3 to month 3 of therapy. Median 23-h acid reflux time was reduced significantly by therapy, from 12.6% at base line to 6.2% on day 3 and 7.2% after 3 months, and there was no significant difference between day 3 and month 3. Although there was no significant change in commonly used indicators of gastro-oesophageal reflux, interindividual variation was great, and multiple linear regression analysis indicated that tolerance, expressed as change in median gastric pH, was related to individual changes in 23-h acid reflux time with a correlation coefficient of -0.43. Infection with H. pylori was diagnosed in 44% of patients and was negatively related to tolerance.
CONCLUSIONS: Our group of patients developed tolerance to the effect of ranitidine on gastric acidity. While gastro-oesophageal reflux did not change significantly in the group, tolerance may seen to contribute to increased gastro-oesophageal reflux in individual patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898414     DOI: 10.3109/00365529609003113

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  8 in total

Review 1.  Treatment of gastroesophageal reflux disease.

Authors:  Michael Pettit
Journal:  Pharm World Sci       Date:  2005-12

Review 2.  Pharmacologic management of gastroesophageal reflux disease.

Authors:  Amarnath Ramakrishnan; Philip O Katz
Journal:  Curr Gastroenterol Rep       Date:  2002-06

Review 3.  Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.

Authors:  J G Hatlebakk; A Berstad
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

4.  Reducing gastric secretions--a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction?

Authors:  K Clark; L Lam; D Currow
Journal:  Support Care Cancer       Date:  2009-03-17       Impact factor: 3.603

Review 5.  Different management for Helicobacter pylori positive and negative patients with gastro-oesophageal reflux disease?

Authors:  J M Lee; C A O'Morain
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

Review 6.  pH, healing rate, and symptom relief in patients with GERD.

Authors:  J Q Huang; R H Hunt
Journal:  Yale J Biol Med       Date:  1999 Mar-Jun

Review 7.  Medical therapy of gastroesophageal reflux disease in secondary and tertiary care settings.

Authors:  G N Tytgat
Journal:  Yale J Biol Med       Date:  1999 Mar-Jun

8.  Pharmacologic Management of Gastroesophageal Reflux Disease.

Authors:  Amarnath Ramakrishnan; Philip O. Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2002-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.